Incidence of adverse events with telmisartan compared with ACE inhibitors: evidence from a pooled analysis of clinical trials
Giuseppe Mancia1, Helmut Schumacher21Universita degli Studi Milano-Bicocca, Ospedale San Gerardo di Monza, Milan, Italy; 2Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim, GermanyAbstract: Telmisartan is indicated for the prevention of cardiovascular events in high-risk patients, based on compa...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2011-12-01
|
| Series: | Patient Preference and Adherence |
| Online Access: | http://www.dovepress.com/incidence-of-adverse-events-with-telmisartan-compared-with-ace-inhibit-a8949 |